The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH CLL 2022 | Combining BTK and BCL-2 inhibitors for the treatment of CLL
John Allan, MD, Weill Cornell Medicine, New York, NY, highlights some important points from his presentation at ESH CLL 2022, which focused on combining Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors in the treatment of chronic lymphocytic leukemia (CLL). Dr Allan briefly discusses the topics covered in this presentation, including clinical trial data, safety and efficacy of these combinations, and more. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
(Consultancy: Abbvie, AstraZenenca, BeiGene, Genentech, Janssen, Pharmacyclics) Research Genentech, Janssen
